Protective effects of bendazac lysine against development of diabetic nephropathy
- VernacularTitle:苄达赖氨酸对大鼠糖尿病肾病的防治作用
- Author:
Xiaoxing YIN
;
Yindi ZHANG
;
Junxian YU
;
Bei ZHANG
;
Jianping SHEN
;
Jun QIU
- Publication Type:Journal Article
- Keywords:
bendazac lysine;
diabetic nephropathy;
mesangial cells;
rats
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2007;12(5):552-557
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the protective effects of bendazac lysine (BDL) on diabetic nephropathy (DN) in vitro and in vivo experiments. METHODS: After rat mesangial cells were cultured in 3 concentrations of BDL for 36 h, the percentages of S phase of cells were determined by flowcytometry; the transforming growth factor β1 (TGF-β1) mRNA level was assayed by reverse transcription PCR; and two main components of extracellular matrix (ECM), collagen Ⅳ and laminin, were determined by radioimmunoassay. Streptozotocin (STZ) induced diabetic rats were administered BDL at doses of 100, 200, 400 mg/kg for 8 weeks. The physical behavior and HbAlC levels of rats were observed. RESULTS: In the presence of high glucose and H2O2, the percentages of S phase of cells were lowered, and TGF-β1 mRNA level, collagen Ⅳ and laminin level were significantly increased. When compared with those in the high glucose group, the percentages of S phase of cells were significantly raised, and the levels of TGF-β1 mRNA, collagen Ⅳ and laminin were statistically decreased. The physical behavior of high BDL treated rats restored to be vibrant, vigorous and weight gaining, and the HbAlC level was significantly reduced. CONCLUSION: BDL has the protective effects against damage caused by DN, and is a potential drug candidate worth further study in preventing and treating DN.
